Androgens in Health and Disease.pdf - E Library
Androgens in Health and Disease.pdf - E Library
Androgens in Health and Disease.pdf - E Library
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
332 Matsumoto<br />
27. Bhas<strong>in</strong> S, Bremner WJ. Cl<strong>in</strong>ical review 85: Emerg<strong>in</strong>g issues <strong>in</strong> <strong>and</strong>rogen replacement therapy. J Cl<strong>in</strong><br />
Endocr<strong>in</strong>ol Metab 1997;82:3–8.<br />
28. De Luca F, Argente J, Cavallo L, et al. Management of puberty <strong>in</strong> constitutional delay of growth <strong>and</strong><br />
puberty. J Pediatr Endocr<strong>in</strong>ol Metab 2001;14:953–957.<br />
29. Houch<strong>in</strong> LD, Rogol AD. Androgen replacement <strong>in</strong> children with constitutional delay of puberty: the<br />
case for aggressive therapy. Baillieres Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab 1998;12:427–440.<br />
30. Soliman AT, Khadir MM, Asfour M. Testosterone treatment <strong>in</strong> adolescent boys with constitutional<br />
delay of growth <strong>and</strong> development. Metabolism 1995;44:1013–1015.<br />
31. Amory JK, Matsumoto AM. The therapeutic potential of testosterone patches. Expert Op<strong>in</strong> Invest<br />
Drugs 1998;7:1977–1988.<br />
32. Cunn<strong>in</strong>gham GR, Cordero E, Thornby JI. Testosterone replacement with transdermal therapeutic<br />
systems. Physiological serum testosterone <strong>and</strong> elevated dihydrotestosterone levels. JAMA 1989;261:<br />
2525–2530.<br />
33. F<strong>in</strong>dlay JC, Place V, Snyder PJ. Treatment of primary hypogonadism <strong>in</strong> men by the transdermal<br />
adm<strong>in</strong>istration of testosterone. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab 1989;68:369–373.<br />
34. F<strong>in</strong>dlay JC, Place VA, Snyder PJ. Transdermal delivery of testosterone. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab<br />
1987;64:266–268.<br />
35. Behre HM, von Eckardste<strong>in</strong> S, Kliesch S, Nieschlag E. Long-term substitution therapy of hypogonadal<br />
men with transscrotal testosterone over 7–10 years. Cl<strong>in</strong> Endocr<strong>in</strong>ol (Oxf) 1999;50:629–635.<br />
36. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone m<strong>in</strong>eral density <strong>in</strong><br />
men over 65 years of age. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab 1999;84:1966–1972.<br />
37. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition <strong>and</strong><br />
muscle strength <strong>in</strong> men over 65 years of age. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab 1999;84:2647–2653.<br />
38. de Lignieres B. Transdermal dihydrotestosterone treatment of “<strong>and</strong>ropause.” Ann Med 1993;25:<br />
235–241.<br />
39. Kunelius P, Lukkar<strong>in</strong>en O, Hannuksela ML, et al. The effects of transdermal dihydrotestosterone <strong>in</strong> the<br />
ag<strong>in</strong>g male: a prospective, r<strong>and</strong>omized, double bl<strong>in</strong>d study. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab 2002;87:1467–1472.<br />
40. Ly LP, Jimenez M, Zhuang TN, et al. A double-bl<strong>in</strong>d, placebo-controlled, r<strong>and</strong>omized cl<strong>in</strong>ical trial of<br />
transdermal dihydrotestosterone gel on muscular strength, mobility, <strong>and</strong> quality of life <strong>in</strong> older men<br />
with partial <strong>and</strong>rogen deficiency. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab 2001;86:4078–4088.<br />
41. Meikle AW, Arver S, Dobs AS, et al. Pharmacok<strong>in</strong>etics <strong>and</strong> metabolism of a permeation-enhanced<br />
testosterone transdermal system <strong>in</strong> hypogonadal men: <strong>in</strong>fluence of application site-a cl<strong>in</strong>ical research<br />
center study. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab 1996;81:1832–1840.<br />
42. Meikle AW, Mazer NA, Moellmer JF, et al. Enhanced transdermal delivery of testosterone across<br />
nonscrotal sk<strong>in</strong> produces physiological concentrations of testosterone <strong>and</strong> its metabolites <strong>in</strong><br />
hypogonadal men. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab 1992;74:623–628.<br />
43. Arver S, Dobs AS, Meikle AW, et al. Long-term efficacy <strong>and</strong> safety of a permeation-enhanced testosterone<br />
transdermal system <strong>in</strong> hypogonadal men. Cl<strong>in</strong> Endocr<strong>in</strong>ol (Oxf) 1997;47:727–737.<br />
44. Kenny AM, Bellantonio S, Gruman CA, et al. Effects of transdermal testosterone on cognitive function<br />
<strong>and</strong> health perception <strong>in</strong> older men with low bioavailable testosterone levels. J Gerontol A: Biol Sci<br />
Med Sci 2002;57:M321–M325.<br />
45. Kenny AM, Prestwood KM, Gruman CA, et al. Effects of transdermal testosterone on bone <strong>and</strong> muscle<br />
<strong>in</strong> older men with low bioavailable testosterone levels. J Gerontol A: Biol Sci Med Sci 2001;56:<br />
M266–M272.<br />
46. Brocks DR, Meikle AW, Boike SC, et al. Pharmacok<strong>in</strong>etics of testosterone <strong>in</strong> hypogonadal men after<br />
transdermal delivery: <strong>in</strong>fluence of dose. J Cl<strong>in</strong> Pharmacol 1996;36:732–739.<br />
47. Bennett NJ. A burn-like lesion caused by a testosterone transdermal system. Burns 1998;24:478–480.<br />
48. Jordan WP Jr. Allergy <strong>and</strong> topical irritation associated with transdermal testosterone adm<strong>in</strong>istration: a<br />
comparison of scrotal <strong>and</strong> nonscrotal transdermal systems. Am J Contact Dermatitis 1997;8:108–113.<br />
49. Parker S, Armitage M. Experience with transdermal testosterone replacement therapy for hypogonadal<br />
men. Cl<strong>in</strong> Endocr<strong>in</strong>ol (Oxf) 1999;50:57–62.<br />
50. Wilson DE, Kaidbey K, Boike SC, Jorkasky DK. Use of topical corticosteroid pretreatment to reduce<br />
the <strong>in</strong>cidence <strong>and</strong> severity of sk<strong>in</strong> reactions associated with testosterone transdermal therapy. Cl<strong>in</strong><br />
Ther 1998;20:299–306.<br />
51. S<strong>in</strong>gh AB, Norris K, Modi N, et al. Pharmacok<strong>in</strong>etics of a transdermal testosterone system <strong>in</strong> men with<br />
end stage renal disease receiv<strong>in</strong>g ma<strong>in</strong>tenance hemodialysis <strong>and</strong> healthy hypogonadal men. J Cl<strong>in</strong><br />
Endocr<strong>in</strong>ol Metab 2001;86:2437–2445.